Halozyme Therapeutics’ (HALO) “Buy” Rating Reiterated at Benchmark

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating restated by investment analysts at Benchmark in a research note issued to investors on Thursday,Benzinga reports. They currently have a $75.00 target price on the biopharmaceutical company’s stock. Benchmark’s target price indicates a potential upside of 31.50% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. HC Wainwright raised their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Down 1.3 %

Shares of NASDAQ:HALO opened at $57.03 on Thursday. The company’s fifty day moving average is $53.07 and its 200-day moving average is $54.56. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a 52 week low of $36.61 and a 52 week high of $65.53. The company has a market capitalization of $7.26 billion, a PE ratio of 16.67, a P/E/G ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 165.13%. Equities research analysts predict that Halozyme Therapeutics will post 4.72 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $29,000. CBIZ Investment Advisory Services LLC acquired a new position in Halozyme Therapeutics in the fourth quarter valued at about $29,000. Smartleaf Asset Management LLC boosted its holdings in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics during the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust grew its position in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 322 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.